Acadia's Nuplazid rebounds in schizophrenia with study win

26th November 2019 Uncategorised 0

Acadia’s Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn’t Nuplazid’s last go at the indication, and now a win from the phase 2 Advance study could help Acadia get over the top. 

More: Acadia's Nuplazid rebounds in schizophrenia with study win
Source: fierce